ArticleInternational journal of clinical oncology2026
Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical data on chimeric antigen receptor (CAR) T-cell therapy in Japanese patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBCL) are limited. This study evaluated the safety and long-term outcomes of CAR T-cell therapy in R/R PMBCL, including the impact of pembrolizumab used as holding (pre-apheresis) and/or bridging (post-apheresis) therapy.
methodsWe retrospectively analyzed patients with R/R PMBCL receiving axicabtagene ciloleucel or lisocabtagene maraleucel at our institution between October 2021 and October 2025. Treatment efficacy and survival outcomes were compared with those of patients with other large B-cell lymphoma (LBCL) treated with CAR T-cell therapy. Pembrolizumab administration as holding and/or bridging therapy was also assessed.
resultsTwelve patients with PMBCL received CAR T-cell therapy, with a median follow-up of 24 months. The overall and complete response rates were both 92%. The 2-year progression-free survival (PFS) and overall survival rates were also 92%. Cytokine release syndrome was limited to grade 2, and immune effector cell-associated neurotoxicity syndrome occurred in one patient. Ten patients received pembrolizumab, which was associated with reduced metabolic tumor volume from leukapheresis to CAR T-cell infusion and manageable immune-related adverse events. Compared with other LBCL, PMBCL demonstrated favorable outcomes, with a 1-year PFS of 92% versus 65% in other LBCL (hazard ratio, 5.25; 95% confidence interval, 0.720-38.21; p = 0.067).
conclusionsCAR T-cell therapy demonstrated durable responses and a manageable safety profile in R/R PMBCL, including in patients receiving pembrolizumab as holding and/or bridging therapy, supporting its use as a promising treatment option.
Indexed as
Identifiers
41968224What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.